// App-Quantinova.ai

: Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Researchers

Presenter

  • Onima Chowdhury

Principal Investigators

  • Nikolas Barkas

  • Gemma Buck

  • Angela Hamblin

  • Ayalew Tefferi

  • Haifa Al-Ali

  • Giovanni Barosi

  • Timothy Devos

  • Heinz Gisslinger

  • Qian Jiang

  • Jean-Jacques Kiladjian

  • Ruben A. Mesa

  • Francesco Passamonti

  • Vincent Ribrag

  • Gary J. Schiller

  • Alessandro M. Vannucchi

  • Daobin Zhou

  • Mary Frances McMullin

  • David Reiser

  • Jim Zhong

  • Robert Peter Gale

  • Adam J. Mead

Medical Centers

  • NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, University of Oxford, Oxford, United Kingdom

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Universitatsklinikum Halle, Halle, Germany

  • Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Medical University of Vienna, Vienna, Austria

  • Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

  • INSERM U976 Hopital Saint Louis, Paris, France

  • Mays Cancer Center at UT Health San Antonio MD Anderson Cencer Center,San Antonio, TX,Stati Uniti

  • Department of Hematology,University of Insubria, Varese, Italy

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Queen's University Belfast, Belfast, United Kingdom

  • Celgene Corporation, Summit, NJ

  • Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom

Locations

  • United Kingdom

  • United States

  • Germany

  • Italy

  • Belgium

  • Austria

  • China

  • France

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Interferon regulatory factor 4

  • BRCA1 associated RING domain 1

  • Calreticulin

  • checkpoint kinase 2

  • DNA methyltransferase 3 alpha

  • E3 ubiquitin-protein ligase CBL

  • Enhancer of zeste homolog 2

  • HRas Proto-Oncogene, GTPase

  • Isocitrate dehydrogenase 1

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • KRAS proto-oncogene, GTPase

  • Tet methylcytosine dioxygenase 2

  • Tumor protein p53

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • Pomalidomide

  • CC-4047

  • TP53

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved